Division of Thoracic Surgery, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins Medical Institutions, Baltimore, MD, USA.
J Gastrointest Surg. 2011 Sep;15(9):1611-7. doi: 10.1007/s11605-011-1605-8. Epub 2011 Jul 2.
This study was conducted to determine if pulmonary metastasectomy (PM) for isolated pancreatic cancer metastases is safe and effective.
This was a retrospective case-control study of patients undergoing PM at our institution from 2000 to 2009 for isolated lung metastasis after resection for pancreatic cancer. Clinical and pathologic data were compared with a matched reference group. Resected neoplasms were immunolabeled for the Dpc4 protein. Kaplan-Meier analysis compared overall survival and survival after relapse.
Of 31 patients with isolated lung metastasis, 9 underwent 10 pulmonary resections. At initial pancreas resection, all patients were stage I or II. Other baseline characteristics were similar between the two groups. Median time from pancreatectomy to PM was 34 months (interquartile range 21-49). During the study, 29/31(90.6%) patients died. There were no in-hospital mortalities or complications after PM. Median cumulative survival was significantly improved in the PM group (51 vs. 23 months, p = 0.04). There was a trend toward greater 2-year survival after relapse in the PM group (40% vs. 27%, p = 0.2).
In patients with isolated lung metastasis from pancreatic adenocarcinoma, this is the first study to show that pulmonary resection can be performed safely with low morbidity and mortality. The improved survival in the PM group may result in part from selection bias but may also represent a benefit of the procedure.
本研究旨在确定孤立性胰腺癌转移灶行肺转移切除术(PM)的安全性和有效性。
这是一项回顾性病例对照研究,纳入了 2000 年至 2009 年期间在我院因胰腺癌切除术后孤立性肺转移而行 PM 的患者。比较了临床和病理数据,并与匹配的对照组进行比较。切除的肿瘤用 Dpc4 蛋白进行免疫标记。Kaplan-Meier 分析比较了总生存期和复发后的生存期。
31 例孤立性肺转移患者中,9 例行 10 例肺切除术。在初始胰腺切除术时,所有患者均为 I 期或 II 期。两组的其他基线特征相似。从胰腺切除术到 PM 的中位时间为 34 个月(四分位距 21-49)。研究期间,31 例患者中有 29 例死亡。PM 后无院内死亡或并发症。PM 组的中位累积生存率显著提高(51 个月 vs. 23 个月,p = 0.04)。PM 组复发后 2 年生存率有升高趋势(40% vs. 27%,p = 0.2)。
在孤立性肺转移的胰腺腺癌患者中,这是第一项表明肺切除术可以安全进行,且发病率和死亡率低的研究。PM 组的生存改善可能部分归因于选择偏倚,但也可能代表该手术的获益。